Tailoring the Lamellarity of Liposomes Prepared by Dual Centrifugation.
Cryo-EM
drug delivery
dual centrifugation
inaccessible surface
lamellarity
lipodisks
liposomes
multilamellar vesicles
small multilamellar vesicles
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
20 Feb 2023
20 Feb 2023
Historique:
received:
21
12
2022
revised:
13
02
2023
accepted:
16
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
Dual centrifugation (DC) is a new and versatile technique for the preparation of liposomes by in-vial homogenization of lipid-water mixtures. Size, size distribution, and entrapping efficiencies are strongly dependent on the lipid concentration during DC-homogenization. In this study, we investigated the detailed structure of DC-made liposomes. To do so, an assay to determine the ratio of inner to total membrane surfaces of liposomes (inaccessible surface) was developed based on either time-resolved or steady-state fluorescence spectroscopy. In addition, cryogenic electron microscopy (cryo-EM) was used to confirm the lamellarity results and learn more about liposome morphology. One striking result leads to the possibility of producing a novel type of liposome-small multilamellar vesicles (SMVs) with low PDI, sizes of the order of 100 nm, and almost completely filled with bilayers. A second particularly important finding is that VPGs can be prepared to contain open bilayer structures that will close spontaneously when, after storage, more aqueous phase is added and liposomes are formed. Through this process, a drug can effectively be entrapped immediately before application. In addition, dual centrifugation at lower lipid concentrations is found to produce predominantly unilamellar vesicles.
Identifiants
pubmed: 36840028
pii: pharmaceutics15020706
doi: 10.3390/pharmaceutics15020706
pmc: PMC9961234
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Swedish Cancer Society
ID : 200987
Références
J Control Release. 2000 Mar 1;65(1-2):271-84
pubmed: 10699287
Microvasc Res. 1986 May;31(3):288-305
pubmed: 2423854
Int J Pharm. 2019 Dec 15;572:118753
pubmed: 31678380
Biochemistry. 1991 Dec 24;30(51):11819-27
pubmed: 1751498
Int J Pharm. 2022 Mar 25;616:121536
pubmed: 35124120
Int J Pharm. 2017 Sep 15;530(1-2):79-88
pubmed: 28733242
Pharmaceutics. 2021 Dec 15;13(12):
pubmed: 34959444
Pharmaceutics. 2022 Sep 07;14(9):
pubmed: 36145639
J Control Release. 2010 Mar 19;142(3):319-25
pubmed: 19925833
Adv Drug Deliv Rev. 2001 Dec 31;53(3):285-305
pubmed: 11744173
J Control Release. 2009 Apr 2;135(1):80-8
pubmed: 19124051
Nat Commun. 2018 Nov 23;9(1):4960
pubmed: 30470753
Eur J Pharm Biopharm. 2020 Aug;153:158-167
pubmed: 32522680
J Colloid Interface Sci. 2020 Oct 15;578:281-289
pubmed: 32531558
Biophys J. 1997 Jul;73(1):258-66
pubmed: 9199790
Biochim Biophys Acta. 1996 Feb 21;1279(1):63-9
pubmed: 8624363
Int J Pharm. 2019 Feb 25;557:1-8
pubmed: 30572079
Biochim Biophys Acta. 1994 Jan 19;1189(2):212-24
pubmed: 8292627
Pharmaceutics. 2019 Jul 24;11(8):
pubmed: 31344836
Biochim Biophys Acta. 2003 Aug 7;1614(2):135-8
pubmed: 12896806
Pharm Res. 2011 Sep;28(9):2261-72
pubmed: 21594716
J Control Release. 1998 Nov 13;55(2-3):261-70
pubmed: 9795078
Chem Phys Lipids. 2001 Jan;109(1):103-12
pubmed: 11163348
Pharmaceutics. 2022 Jul 22;14(8):
pubmed: 35893783
Int J Pharm. 2003 Apr 30;256(1-2):123-31
pubmed: 12695018
J Control Release. 2008 Jan 4;125(1):16-24
pubmed: 18023907
Biophys Chem. 2005 Feb 1;113(2):183-92
pubmed: 15617826
Int J Pharm X. 2021 Jun 05;3:100085
pubmed: 34159313
Int J Nanomedicine. 2022 Oct 31;17:5081-5097
pubmed: 36340183
Pharmaceutics. 2021 Nov 30;13(12):
pubmed: 34959327
Biophys J. 1996 Feb;70(2):595-608
pubmed: 8789079
J Colloid Interface Sci. 2016 Dec 15;484:86-96
pubmed: 27592189
Int J Pharm. 2001 Apr 17;217(1-2):161-72
pubmed: 11292552